Checkpoint Therapeutics completes acquisition by Sun Pharma for $4.10/share plus CVR

Checkpoint Therapeutics, Inc.

Merger closed May 30, 2025; Checkpoint becomes wholly owned subsidiary of Sun Pharma.
Shareholders receive $4.10 cash per share plus non-tradable CVR (up to $0.70 contingent on EU regulatory milestones for cosibelimab).
Common stock delisted from Nasdaq; Company intends to suspend SEC reporting obligations.
All prior directors and officers resigned; Abhay Gandhi (President), Sudhir Valia (Director), Zvi Albert (CFO) appointed from Sun Pharma.
Founders Agreement, Management Services Agreement, Board Advisory Services Agreement terminated at closing.

item 1.02item 5.02item 2.01item 3.01item 3.03item 5.03item 5.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Abhay Gandhi

Director

Checkpoint Therapeutics, Inc.

Effective: 2025-05-30
Filed: May 30, 2025 23:59 UTC

(ii) Abhay Gandhi and Sudhir Valia, the directors of Merger Sub immediately prior to the Effective Time, became directors of the Company

Appointed

Zvi Albert

Chief Financial Officer

Checkpoint Therapeutics, Inc.

Effective: 2025-05-30
Filed: May 30, 2025 23:59 UTC

(iv) Zvi Albert, the Chief Financial Officer of Merger Sub immediately prior to the Effective Time, became the Chief Financial Officer of the Company

Appointed

Sudhir Valia

Director

Checkpoint Therapeutics, Inc.

Effective: 2025-05-30
Filed: May 30, 2025 23:59 UTC

(ii) Abhay Gandhi and Sudhir Valia, the directors of Merger Sub immediately prior to the Effective Time, became directors of the Company

Appointed

Abhay Gandhi

President

Checkpoint Therapeutics, Inc.

Effective: 2025-05-30
Filed: May 30, 2025 23:59 UTC

(iii) Abhay Gandhi, the President of Merger Sub immediately prior to the Effective Time, became the President of the Company

Source: SEC EDGAR

accession 0001104659-25-054628

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.